# Eric Fain

> Eric S. Fain, M.D. is the President and CEO of Procyrion, the Houston medical device company building Aortix, a percutaneous micropump roughly the size of a AA battery that is threaded into the aorta to boost blood flow and unload failing hearts. A Stanford-trained physician who never practiced clinically, Fain spent a decade at defibrillator pioneer Ventritex, then two decades climbing to Group President of St. Jude Medical and SVP at Abbott, before returning to startup life in 2018. He closed a $57.7M Series E in 2024 and serves as Lead Independent Director of Orchestra BioMed.

- **Role:** President and CEO at Procyrion, Inc.
- **Organizations:** Procyrion, Inc., Orchestra BioMed, St. Jude Medical (former), Abbott (former), Ventritex, Inc. (former)
- **Nationality:** American
- **Education:** M.D., Stanford University School of Medicine, Sc.B., applied math/biology, Brown University
- **Known for:** Led Procyrion's $57.7M Series E financing (2024) and earlier rounds, Rose to Group President of St. Jude Medical, running its entire worldwide portfolio, Helped advance early implantable defibrillator technology at Ventritex

## Career timeline

- **1987** — Earns M.D. from Stanford; joins defibrillator startup Ventritex for what was meant to be a one-year research stint
- **1987-1997** — Stays a decade at Ventritex, drawn into the world of implantable defibrillators
- **1997** — Joins St. Jude Medical as VP, Systems Development after it acquires Ventritex
- **2007** — Becomes President of St. Jude Medical's Cardiac Rhythm Management Division
- **2012** — Named President of the Implantable Electronic Systems Division
- **2014** — Becomes Group President of St. Jude Medical, overseeing global sales, marketing, R&D, clinical and regulatory
- **2017** — Becomes SVP and Group President, Cardiovascular and Neuromodulation at Abbott after its St. Jude acquisition
- **2018** — Named President and CEO of Procyrion, effective July 23; joins Orchestra BioMed board in November
- **2023** — Becomes Lead Independent Director of Orchestra BioMed
- **2024** — Closes $57.7M Series E to fund the DRAIN-HF pivotal trial for Aortix

## Achievements

- Led Procyrion's $57.7M Series E financing (2024) and earlier rounds
- Rose to Group President of St. Jude Medical, running its entire worldwide portfolio
- Helped advance early implantable defibrillator technology at Ventritex
- Guided Procyrion's Aortix device into the DRAIN-HF pivotal IDE trial
- Serves as Lead Independent Director of Orchestra BioMed

## Latest updates

- **2024-02** — Procyrion closed a $57.7M Series E, including conversion of $10M of interim financing, to fund the DRAIN-HF pivotal trial and prepare for commercialization.

## Links

- Website: https://procyrion.com
- LinkedIn: http://www.linkedin.com/in/eric-fain-149408b

---

Profile page: https://yespress.io/eric-fain
Published by YesPress — https://yespress.io
Last updated: 2026-06-12